A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bepler, G.
Oh, Y.
Burris, H.
Cleverly, A.
Lahn, M.
Herbst, R. S.
机构：
[1] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Sarah Cannon Res Inst, Ashville, TN USA
[4] Eli Lilly & Co, Erlwood, England
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7543
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of mitonafide in non-small cell lung cancer (NSCLC)
    Casado, A
    Rosell, R
    GarciaGomez, R
    DiazRubio, E
    PerezManga, G
    Font, A
    Benavides, A
    Martin, M
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) : 415 - 417
  • [42] Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
    Zhou, Dongchu
    Luo, Xia
    Zhou, Zhen
    Zeng, Xiaohui
    Wan, Xiaomin
    Tan, Chongqing
    Liu, Qiao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [43] Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer
    Lebeau, Bernard
    Chouaid, Christos
    Baud, Mariette
    Masanes, Marie-Josee
    Febvre, Michel
    LUNG CANCER, 2010, 67 (02) : 188 - 193
  • [44] Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer
    Igawa, Satoshi
    Yamamoto, Nobuyuki
    Ueda, Shinya
    Ono, Akira
    Nakamura, Yukiko
    Tsuya, Asuka
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 741 - 744
  • [45] EVALUATION OF CISPLATIN(C), PEMETREXED(P) AND BEVACIZUMAB(B) AS SECOND- OR THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Yoshida, Tsukasa
    Nakamura, Masayuki
    Hirahara, Nana
    Kumano, Tomomi
    Okamoto, Masaki
    Ichiki, Masao
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S484 - S484
  • [46] Biweekly paclitaxel as second-line treatment in advanced non-small cell lung-cancer (NSCLC). A phase II study of the Lung Cancer Galician Group
    Vazquez-Estevez, S.
    Firvida, J.
    Huidobro, G.
    Leon, L.
    Lazaro, M.
    Salgado, M.
    Mel, J.
    Grande, C.
    Perez, E.
    Campos, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] A Trial of Autologous Ex vivo-expanded NK Cell-enriched Lymphocytes with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer as Second- or Third-line Treatment: Phase IIa Study
    Yang, Young Jun
    Park, Ji Chan
    Kim, Hoon Kyo
    Kang, Jin Hyoung
    Park, Suk Young
    ANTICANCER RESEARCH, 2013, 33 (05) : 2115 - 2122
  • [48] PHASE II STUDY OF AMRUBICIN (AMR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: HOKKAIDO LUNG CANCER CLINICAL STUDY GROUP TRIAL (HOT) 0901
    Itoh, K.
    Harada, T.
    Takamura, K.
    Kikuchi, E.
    Ohizumi, S.
    Sugawara, S.
    Maemondo, M.
    Fujita, Y.
    Kinoshita, I.
    Inoue, A.
    Hommura, F.
    Katsuura, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 113 - 113
  • [49] Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
    I Ray-Coquard
    L Favier
    B Weber
    C Roemer-Becuwe
    P Bougnoux
    M Fabbro
    A Floquet
    F Joly
    A Plantade
    D Paraiso
    E Pujade-Lauraine
    British Journal of Cancer, 2013, 108 : 1771 - 1777
  • [50] Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
    Ray-Coquard, I.
    Favier, L.
    Weber, B.
    Roemer-Becuwe, C.
    Bougnoux, P.
    Fabbro, M.
    Floquet, A.
    Joly, F.
    Plantade, A.
    Paraiso, D.
    Pujade-Lauraine, E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1771 - 1777
12345